Hikma shares up 7%
Unlock the Editor’s Digest for free
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
Hikma Pharmaceuticals is topping the FTSE All Share this morning after the company reported better than expected results for 2016.
The generic drug specialist earlier said that a fall in operating profits last year was not as bad as expected, while revenues were a touch better than expectations.
Hikma also slightly raised its dividend for last year and predicted revenue growth of 10 per cent in 2017.
Comments